Terms: = Ovarian cancer AND SERPINE1, PAI, PAI-1, PAI1, PLANH1 AND Treatment
33 results:
1. Continuous Administration of Anti-VEGFA Antibody Upregulates pai-1 Secretion from ovarian cancer Cells via miR-143-3p Downregulation.
Yagi T; Sawada K; Miyamoto M; Shimizu A; Oi Y; Toda A; Nakamura K; Kinose Y; Kodama M; Hashimoto K; Kimura T
Mol Cancer Res; 2023 Oct; 21(10):1093-1106. PubMed ID: 37327051
[TBL] [Abstract] [Full Text] [Related]
2. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS).
Siddiqui S; Mateen S; Ahmad R; Moin S
J Assist Reprod Genet; 2022 Nov; 39(11):2439-2473. PubMed ID: 36190593
[TBL] [Abstract] [Full Text] [Related]
3. Small extracellular vesicles from malignant ascites of patients with advanced ovarian cancer provide insights into the dynamics of the extracellular matrix.
Bortot B; Apollonio M; Rampazzo E; Valle F; Brucale M; Ridolfi A; Ura B; Addobbati R; Di Lorenzo G; Romano F; Buonomo F; Ripepi C; Ricci G; Biffi S
Mol Oncol; 2021 Dec; 15(12):3596-3614. PubMed ID: 34614287
[TBL] [Abstract] [Full Text] [Related]
4. Oleuropein is a natural inhibitor of pai-1-mediated proliferation in human ER-/PR- breast cancer cells.
Tzekaki EE; Geromichalos G; Lavrentiadou SN; Tsantarliotou MP; Pantazaki AA; Papaspyropoulos A
Breast Cancer Res Treat; 2021 Apr; 186(2):305-316. PubMed ID: 33389400
[TBL] [Abstract] [Full Text] [Related]
5. Integrative analysis of the common genetic characteristics in ovarian cancer stem cells sorted by multiple approaches.
Zhang X; Su Y; Wu X; Xiao R; Wu Y; Yang B; Wang Z; Guo L; Kang X; Wang C
J Ovarian Res; 2020 Sep; 13(1):116. PubMed ID: 32977853
[TBL] [Abstract] [Full Text] [Related]
6. LncRNA TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in epithelial ovarian cancer cells.
Li T; Chen Y; Zhang J; Liu S
Medicine (Baltimore); 2018 Sep; 97(36):e12131. PubMed ID: 30200102
[TBL] [Abstract] [Full Text] [Related]
7. Investigation of hypoxia networks in ovarian cancer via bioinformatics analysis.
Zhang K; Kong X; Feng G; Xiang W; Chen L; Yang F; Cao C; Ding Y; Chen H; Chu M; Wang P; Zhang B
J Ovarian Res; 2018 Feb; 11(1):16. PubMed ID: 29482638
[TBL] [Abstract] [Full Text] [Related]
8. Aberrant serpine1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer.
Pan JX; Qu F; Wang FF; Xu J; Mu LS; Ye LY; Li JJ
Arch Gynecol Obstet; 2017 Dec; 296(6):1145-1152. PubMed ID: 28975405
[TBL] [Abstract] [Full Text] [Related]
9. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract] [Full Text] [Related]
10. Biomarkers in Breast cancer: Where Are We and Where Are We Going?
Duffy MJ; Walsh S; McDermott EW; Crown J
Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
[TBL] [Abstract] [Full Text] [Related]
11. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The cancer Genome Atlas.
Seagle BL; Yang CP; Eng KH; Dandapani M; Odunsi-Akanji O; Goldberg GL; Odunsi K; Horwitz SB; Shahabi S
Gynecol Oncol; 2015 Jul; 138(1):159-64. PubMed ID: 25958320
[TBL] [Abstract] [Full Text] [Related]
12. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
Mashiko S; Kitatani K; Toyoshima M; Ichimura A; Dan T; Usui T; Ishibashi M; Shigeta S; Nagase S; Miyata T; Yaegashi N
Cancer Biol Ther; 2015; 16(2):253-60. PubMed ID: 25587663
[TBL] [Abstract] [Full Text] [Related]
13. Oral carcinogenesis is not achieved in different carcinogen-treated pai-1 transgenic and wild-type mouse models.
Avgoustidis D; Nisyrios T; Nkenke E; Lijnen R; Ragos V; Perrea D; Donta I; Vaena A; Yapijakis C; Vairaktaris E
In Vivo; 2012; 26(6):1001-5. PubMed ID: 23160684
[TBL] [Abstract] [Full Text] [Related]
14. Transforming growth interacting factor expression in leiomyoma compared with myometrium.
Yen-Ping Ho J; Man WC; Wen Y; Polan ML; Shih-Chu Ho E; Chen B
Fertil Steril; 2010 Aug; 94(3):1078-83. PubMed ID: 19524896
[TBL] [Abstract] [Full Text] [Related]
15. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis.
Nanjundan M; Cheng KW; Zhang F; Lahad J; Kuo WL; Schmandt R; Smith-McCune K; Fishman D; Gray JW; Mills GB
Mol Oncol; 2008 Aug; 2(2):164-81. PubMed ID: 19383336
[TBL] [Abstract] [Full Text] [Related]
16. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression.
Li P; Maines-Bandiera S; Kuo WL; Guan Y; Sun Y; Hills M; Huang G; Collins CC; Leung PC; Gray JW; Auersperg N
Int J Cancer; 2007 May; 120(9):1863-73. PubMed ID: 17266044
[TBL] [Abstract] [Full Text] [Related]
17. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Whitley BR; Beaulieu LM; Carter JC; Church FC
Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
[TBL] [Abstract] [Full Text] [Related]
18. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract] [Full Text] [Related]
19. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
Yagyu T; Kobayashi H; Wakahara K; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
FEBS Lett; 2004 Oct; 576(3):408-16. PubMed ID: 15498571
[TBL] [Abstract] [Full Text] [Related]
20. [Conventional and experimental prognostic factors in ovarian cancer].
Sehouli J; Mustea A; Könsgen D; Lichtenegger W
Zentralbl Gynakol; 2004 Oct; 126(5):315-22. PubMed ID: 15478050
[TBL] [Abstract] [Full Text] [Related]
[Next]
